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ERK1/2 Is Highly Phosphorylated in Melanoma
Metastases and Protects Melanoma Cells from
Cisplatin-Mediated Apoptosis
Alireza Mirmohammadsadegh1, Rodrigo Mota1, Annett Gustrau1, Mohammed Hassan1, Sandeep Nambiar1,
Alessandra Marini1, Hans Bojar2, Andrea Tannapfel3 and Ulrich R. Hengge1
Activation (phosphorylation) of mitogen-activated protein kinase (MAPK) signal transduction through BRAF and
RAS causes a variety of functional effects including cell survival and cell death. In this study, we observed high
extracellular signal-regulated kinase (ERK)1/2 phosphorylation levels in clinical melanoma metastases and various
melanoma cell lines. Treatment of melanoma cell lines with cisplatin, a potent antitumor agent, increased the level
of phosphorylated-ERK (P-ERK)1/2 and enhanced chemoresistance through activation of the cell survival protein
90-kDa ribosomal S6 kinase (RSK)1. The mitogen-activated protein kinase kinase (MEK) inhibitor (U0126) was able
to block this effect and reduced cell viability and sensitized cells to cisplatin-induced apoptosis, as shown by PARP
cleavage, caspase 3 expression, and annexin-V staining. In conclusion, the MAP kinase–ERK pathway is activated in
melanoma and reduces the sensitivity of melanoma to cisplatin. Thus, inhibition of ERK1/2 in combination with
selected chemotherapeutic agents may hold promise for more effective therapy of melanoma.
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INTRODUCTION
Extracellular signal-regulated kinase (ERK) is a member of the
mitogen-activated protein kinase (MAPK) family, which
regulates essential cellular functions like proliferation,
differentiation, cell survival, and cell death (Cowley et al.,
1994; Hoshino et al., 1999). ERK is activated by numerous
extracellular agents such as growth factors, cytokines,
hormones, and tumor promotors (Johnson and Vaillancourt,
1994; Robinson and Cobb, 1997; He et al., 1999).
Constitutive activation of the ERK pathway has been
described in cell lines derived from pancreas, colon, lung,
ovary, and kidney cancer (Hoshino et al., 1999). In
melanoma, activation of ERK1/2 was observed by immuno-
histochemistry in 54% of primary and 33% of metastastic
melanomas, respectively (Jorgensen et al., 2003). One reason
for this activation seems to be a somatic missense mutation of
the BRAF gene, which was reported to occur within the
kinase domain in 66% of malignant melanomas and shown to
cause elevated kinase activity from RAS to mitogen-activated
protein kinase kinase (MEK)1/2 and ERK1/2 (Davies et al.,
2002). However, this mutation was also observed in 82%
of nevi, suggesting that the RAS/RAF/MAPK pathway is a
critical step in the initiation of melanocyte neoplasias but
that by itself seems insufficient to cause melanomagenesis
(Pollock et al., 2003). Furthermore, the identification of
factors that modulate the dysbalance in favor of ERK
may provide additional targets for effective therapy. In
melanoma, epidermal growth factor (EGF) is one of the
growth factors that can shift the balance in favor of ERK and
may eventually cause tumor progression (Mirmohammadsa-
degh et al., 2005).
To answer questions related to ERK regulation during
chemotherapy against melanoma, we chose cisplatin, one of
the most potent antitumor agents, with clinical activity
against a variety of solid tumors (Siddik, 2003). Cisplatin
interacts with DNA to form DNA adducts and activates
several signal pathways like MAPK, p53, AKT, and p73
(Siddik, 2003). It has been reported that cisplatin is able to
activate p38 MAPK in different human cell lines and that its
inhibition causes resistance to chemotherapy (Losa et al.,
2003). A recent study demonstrated that cisplatin-induced
apoptosis occurred through the p38 MAPK and not through
the MEK1/2–ERK1/2 pathway (Wu et al., 2005). Other studies
suggested that ERK1/2 activation by cisplatin induced cell
death (Wang et al., 2000; Arany et al., 2004; Choi et al.,
2004). In contrast, the inhibition of ERK enhanced the
sensitivity to cisplatin in ovarian cancer by accumulation
of p53 (Persons et al., 1999). These conflicting findings of
pro- and antiapoptotic functions may reflect differences in the
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cellular context and target proteins regulated by ERK such as
p53 and 90-kDa ribosomal S6 kinase (RSK) that are involved
in apoptosis and cell survival. The RSK family of serine/
threonine kinases regulates gene expression by phosphorylat-
ing a number of transcription factors (Chen et al., 1993). In
humans, the RSK family consists of four isoforms (RSK1–4)
and two structurally related proteins, called RSK-like protein
kinase (RLPK/MSK1)-A and RSK-B (MSK2). RSK family
members are unusual among serine/threonine kinases in that
they contain two distinct kinase domains, both of which are
catalytically functional (Fisher and Blenis, 1996).
Activated RSK has both cytoplasmic and nuclear sub-
strates. RSK plays an active role in nuclear signaling by
phosphorylating the cyclic AMP response element-binding
protein (Xing et al., 1996), c-Fos (Chen et al., 1993), and IkB
(Schouten et al., 1997). Phosphorylation of Bad (Bonni et al.,
1999; Shimamura et al., 2000) and C/EBPb (Buck et al., 2001)
by RSK can protect cells from apoptosis. Moreover, RSK
phosphorylates histone H3 (Sassone-Corsi et al., 1999),
suggesting that RSK may regulate chromatin remodeling.
In this study, we examined the importance of P-ERK in
malignant melanoma metastases as well as its modulation
after treatment with recombinant human EGF (rEGF),
cisplatin, and the MEK inhibitor U0126. The manipulation
of ERK activity by specific inhibitors provided evidence that
its antiapoptotic function in melanoma is mediated through
the activation of the survival protein RSK1.
RESULTS
High P-ERK in melanoma metastases
ERK1/2 was constitutively expressed in normal human
melanocytes (NHM) and different melanoma cell lines as
well as in most (27 of 31; 87%) investigated melanoma
metastases of patients before receiving chemotherapy
(Figure 1). In contrast, phosphorylated ERK1/2 levels were
low in NHM, upregulated in melanoma cell lines, and highly
abundant in 25 of 31 (81%) melanoma metastases (Figure 1).
Immunohistochemically, ERK and activated ERK could be
demonstrated in the cytoplasm and nucleus of melanoma
cells, respectively (Figure 2b and d). In a recent study, we
have demonstrated high levels of EGFR on NHM as well as
on melanoma metastases (Mirmohammadsadegh et al., 2005)
and have suggested EGF as one important growth factor
responsible for ERK phosphorylation in melanoma. Therefore,
we confirmed the EGFR expression on the melanoma cell
lines used in this study (Figure 3). Western blot experiments
demonstrated high EGFR levels on NHM and A375 cells and
HaCaT (immortalized epithelial cell line as positive control)
and revealed low levels on BLM and MV3 cells, respectively
(Figure 3).
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Figure 1. Western blot analysis of ERK1/2 and P-ERK1/2. ERK1/2 was constitutively expressed in nearly all investigated samples. ERK1/2 phosphorylation
was low in NHM, showed basal levels in melanoma cell lines (BLM, MV3, M13, and A375) and was high in most of the melanoma metastases. Equal
loading was confirmed by a-tubulin.
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Figure 2. Immunohistochemistry of activated ERK1/2.
(a and b) A representative sample of a metastastic melanoma showed, upon
higher magnification, predominant cytoplasmatic ERK1/2 staining.
(c) A corresponding section showed intense nuclear staining with P-ERK1/2.
(*d) Upon higher magnification, most cells contained cytoplasmatic and
pronounced nuclear staining. Of note, some tumor cells were negative for
P-ERK1/2. The appropriate isotype controls showed no staining (data not
shown). Bar¼ 2 mM in (a), 4 mM in (c), and 10 mM in (b) and (d), respectively.
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Figure 3. Expression of EGFR. NHM and various melanoma cell lines (A375,
BLM, MV3, and M13) were analyzed by Western blot analysis. NHM and
A375 cells showed the highest EGFR levels, whereas BLM cells had
significantly lower amounts of EGFR. HaCaT cells (immortalized epithelial
cell line) were used as positive control.
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Phosphorylation of ERK by rEGF
Next, we investigated the effect of rEGF on ERK phospho-
rylation of NHM and A375 cells, known to contain high
levels of EGFR. rEGF was able to induce expression and
activation of ERK1/2 in NHM and A375 cells as early as after
5 minutes (Figure 4). This finding correlated with the effect of
EGF on proliferation of NHM, where proliferation has been
shown 24 hours after treatment with rEGF (Mirmohammad-
sadegh et al., 2005).
Effect of cisplatin and U0126 on melanoma cell viability and
apoptosis
Next we analyzed, if treatment with cisplatin, a commonly
used anticancer drug as well as specific inhibition of the
MAPK pathway, were able to reduce viability of melanoma
cell lines and attempted to explore how these drugs affected
ERK activation in vitro (Figure S1).
Different melanoma cell lines, A375, BLM, MV3, and M13
were used to investigate the effect of cisplatin in combination
with the MEK1/2 inhibitor U0126 with regard to cell
viability, as measured by conversion of 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to for-
mazan, and cell proliferation/cells in S-phase, as measured
by 5-bromodeoxyuridine (BrdU) incorporation. We observed
that most melanoma cell lines treated with cisplatin and
U0126 showed a significant decrease in cell survival
(Figure 5a) and proliferation (Figure 5b) over cisplatin
treatment alone, in particular at lower concentrations
(10 and 20 mM), whereas MV3 and BLM cells were less
sensitive to different concentrations (Figure 5a and b).
Collectively, these results strongly indicate that cisplatin-
mediated inhibition of survival and proliferation of melano-
ma cells is enhanced in the presence of the MEK inhibitor
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Figure 4. Effect of rEGF on NHM and A375 cells. rEGF induced expression
and activation of ERK1/2 in (a) NHM and (b) A375. Note that the effect lasted
for up to 24 hours, probably owing to the limited stability of EGF. Equal
loading was confirmed by a-tubulin.
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Figure 5. MTT and BrdU assays. (a) The effects of U0126 in combination with cisplatin on viability of different melanoma cell lines are shown. Melanoma
cell lines were pretreated with 25 mM U0126 for 3 hours and co-incubated with increasing concentrations of cisplatin for 24 hours. The co-treatment of cisplatin
and U0126 exhibited greater reduction in (a) cell viability and (b) proliferation than cisplatin monotherapy in most of the investigated melanoma cell lines.
The variation was considered significant when the coefficient of variation (CV) was greater than 0.2*.
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U0126 and that these inhibitory effects are more significant at
lower cisplatin concentrations for most melanoma cell lines
investigated.
Furthermore, following combination therapy, 2.48 times
more BLM cells and 1.93 times more A375 cells became
annexin-V-positive, respectively (Figure 6a and b), when
compared with cells treated with cisplatin only. The MEK
inhibitor U0126 alone had no effect on apoptosis (Figure 6a
and b).
Effect of cisplatin on ERK1/2 regulation
Given that ERK1/2 was phosphorylated in melanoma
metastases and cisplatin being a potent anticancer drug, it
was important to study the effect of cisplatin with regard to
the phosphorylation status on ERK1/2. We observed increas-
ing phosphorylation of ERK1/2 after treatment of different
melanoma cell lines with 100mM cisplatin (Figure 7). This
upregulation correlated with a high expression of cleaved
poly (ADP-ribose) polymerase (PARP), an apoptosis marker
(Figure 7). Next, the role of ERK1/2 in the regulation of
apoptosis was investigated in more detail.
Regulation of apoptosis-related proteins by cisplatin and U0126
Next, the time course of cisplatin monotherapy and cisplatin/
U0126 combination therapy was analyzed with regard to
P-ERK1/2 activation (Figure 8). Cisplatin induced a time-
dependent phosphorylation of ERK1/2 in A375 cells with a
maximum at 12 hours (Figure 8a). The proapoptotic proteins
cleaved PARP and caspase 3 were detected between 12 and
24 hours, which confirmed the occurrence of apoptosis (Figure
8a). Furthermore, the activation of the tumor suppressor
protein p53 on different serine residues (P-serine at position
6, 9, 15, 20, 37, and 392) was investigated using phosphor-
ylation-specific anti-serine antibodies. Only serine at position
6 was phosphorylated by cisplatin at 12 hours, being consistent
with ongoing apoptosis (Figure 8a). Interestingly, at the same
time point, the cell-survival protein RSK1 was also strongly
activated by cisplatin in A375 cells (Figure 8a) and BLM cells
(Figure 9a), suggesting that cisplatin-treated cells initially tried
to avoid apoptosis by activation of cell-survival proteins, but
ultimately cell death occurred. Furthermore, the activation of
the cell survival protein P-RSK1 was inhibited by U0126
(Figures 8b and 9b).
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Figure 6. Annexin-V staining was performed on melanoma cell lines (a) BLM and (b) A375 treated with 25mM U0126, 100 mM cisplatin alone, and in
combination for 24 hours. U0126 single treatment did not induce apoptosis in (a) BLM and (b) A375 cells lines. (a and b) Cisplatin increased the rate of
annexin-V-positive cells in both cell lines. Upon cisplatin/U0126 co-treatment, a significant percentage of (a) BLM and (b) A375 cells became annexin-V
positive. Cisplatin/U0126 co-treatment induced higher rates of apoptosis than individual treatment alone.
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Figure 7. Effect of cisplatin on ERK1/2 phosphorylation. Different melanoma
cell lines were treated with 100 mM cisplatin for 24 hours. Cisplatin
induced the phosphorylation of ERK1/2 and the cleavage of PARP in A375,
BLM, MV3, and M13 cells. The level of ERK1/2 expression was unaffected.
a-Tubulin was used as internal control.
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To elucidate the molecular mechanism of cisplatin-
mediated apoptosis in melanoma cells and its enhancement
upon inhibition of MEK/ERK pathway, we compared the
regulation of apoptosis-related proteins post-cisplatin treat-
ment to co-treatment of cisplatin and U0126 in A375 and
BLM melanoma cells. First, we demonstrated that cisplatin-
induced time-dependent phosphorylation of ERK1/2 in A375
and BLM cells was abolished upon co-treatment of cisplatin
and U0126 (Figures 8a and b and 9a and b), whereas the
pattern of cisplatin-induced phosphorylation of p38 remained
unchanged upon co-treatment of cisplatin and U0126 (Figure
8a and b). We also observed an induction of proteins related
to apoptosis from both intrinsic (Bcl-2 and Bax) and extrinsic
apoptotic pathways (caspases 9, 8, and 3) as well as a more
pronounced PARP cleavage upon co-treatment of cisplatin/
U0126 in both A375 and BLM cells (Figures 8a and b and
9a and b).
These data provide evidence that activated ERK1/2 seems
to phosphorylate different antiapoptotic proteins that aim to
rescue cells from death conditions.
Cisplatin-activated ERK1/2 interacts with p53 and RSK1
in A375 cells but only with RSK1 in BLM cells
As described in the literature, activated ERK1/2 may exert
opposing functions such as cell death and cell survival
(Persons et al., 1999; Wang et al., 2000; Arany et al., 2004;
Choi et al., 2004; Wei et al., 2004). Therefore, to analyze the
role of activated ERK1/2 in melanoma was anti- or
proapoptotic, A375 and BLM melanoma cell lines were
treated with cisplatin alone or in combination with U0126,
and the interaction of P-ERK1/2 with either P-p53 at serine
position 6 or P-RSK1 was investigated using immunopreci-
pitation and Western blot techniques (Figure 10). In A375
cells, cisplatin-activated ERK1/2 interacted with p53 as well
as with RSK1 (Figure 10a). Inhibition of ERK1/2 phosphoryla-
tion by U0126 and treatment with cisplatin prevented this
interaction (Figure 10a), suggesting that cisplatin-activated
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Figure 8. Effect of cisplatin and U0126 on the expression of ERK1/2, p38,
and apoptosis-related proteins in A375 cells. (a) Western blot analysis of
A375 after treatment with 100 mM cisplatin. Cisplatin-induced
phosphorylation of ERK1/2 and p38 with a maximum at 12 hours. Cleavage of
caspases 8 and 9 was observed after 24 and 48 hours, respectively. Cleaved
PARP and caspase 3 were induced between 12 and 24 hours. Bcl-2
decreased, whereas Bax increased with time. Cisplatin-induced serine
phosphorylation of p53 at amino acid position 6 and activation of the survival
protein RSK1 were detected at 12 hours. (b) A375 cells were pre-incubated
with 25mM U0126 for 3 hours before treatment with 100 mM cisplatin. Every
6 hours U0126 was replaced due to limited stability. U0126 strongly inhibited
the activation of ERK1/2, whereas it had no effect on cisplatin-induced P-p38
and p38, suggesting a different regulatory pathway. Caspases 8 and 9 were
cleaved earlier and stronger upon combination treatment. The combination of
cisplatin and U0126 induced stronger cleavage of PARP and caspase 3 as
cisplatin alone. a-tubulin confirmed equal loading and quality of protein
extract.
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Figure 9. Effect of cisplatin and U0126 on expression of ERK1/2, p38, and
apoptosis-related proteins in BLM cells. (a) Cisplatin-induced activation of
ERK1/2 showed a maximum at 24 hours. P38 was phosphorylated by cisplatin
after 24 hours, although weaker than in A375 cells. Cleavage of caspases 8
and 9 occurred after 24 hours. Time-dependent upregulation of Bcl-2 and Bax
was detectable. Cleavage of PARP and caspase 3 was also induced by
cisplatin with a maximum at 24 hours. Cisplatin-induced activation of RSK1
occurred at 6 hours with a maximum at 24 hours. (b) Upon co-incubation with
U0126 (25 mM) and cisplatin (100 mM), the activation of ERK1/2 was inhibited
by U0126 and cisplatin was unable to revert this effect. Constant levels of p38
but an upregulation of P-p38 expression were observed at 48 hours. Like in
A375 cells, the cleavage of PARP and caspase 3 was strongly induced and
persisted between 24 and 48 hours. a-tubulin confirmed equal loading and
quality of protein extract.
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ERK1/2 directly interacts with p53 and RSK1 to phosphorylate
these proteins at serine position 6 (p53) and at threonine/
serine positions 359 and 363, respectively (Figure 10a). In
contrast, there was no significant interaction between
P-ERK1/2 and p53 in BLM cells irrespective of treatment
with cisplatin or U0126 (Figure 10b). The strong activation of
RSK1 under apoptotic conditions in BLM cells may be the
reason for their lower sensitivity to cisplatin and the delayed
activation of proapoptotic proteins like PARP and caspase 3
in comparison with A375 cells (Figures 8a and b, 9a and b,
and 10b). Furthermore, we observed a weaker interaction
between total ERK1/2 and RSK1 after cisplatin treatment in
comparison with P-ERK1/2 interacting with RSK1 in A375
and BLM cells (Figure 10c). In the same experiment, we could
not detect such an interaction with p53 (data not shown).
These data demonstrate that for an effective interaction with
RSK1 and p53, the activated form of ERK1/2 is imperative.
Importantly, melanoma cell lines and four metastasis samples
were also analyzed with regard to their P-ERK1/2 and P-RSK1
status (Figure S2). Both melanoma cell lines and four
metastasis patient samples showed elevated P-ERK1/2. The
BLM melanoma cell line and two out of the four melanoma
metastasis patients that had elevated P-ERK1/2 also showed
elevated P-RSK1, suggesting a correlation.
To corroborate these findings, we used siRNA against
ERK1/2 to determine its effects on active RSK1 in the presence
of cisplatin (Figure 11). While at least the p44 band of ERK
was completely blocked by specific siRNA, P-RSK1 became
undetectable in A375 cells and was strongly reduced in BLM
cells, demonstrating their regulation by ERK1/2 (Figure 11).
To investigate the effect of RSK1 on cell death, the
expression of RSK1 was reduced by specific siRNA (Figure
12a) before incubation of the cells with cisplatin for 24 hours
(Figure 12b). A375 cells with reduced levels of RSK1 were
more sensititve to cisplatin-mediated cell death in compar-
ison with cells exposed to cisplatin only, as demonstrated by
cleaved PARP (Figure 12b).
In summary, we provide evidence for a crosstalk between
proliferation/cell survival pathways activated by the ERK
cascade and the growth arrest/apoptosis function of the tumor
suppressor protein p53 and the survival protein RSK1. It
seemed that cisplatin-mediated activation of ERK1/2 led to
phosphorylation of two proteins with opposing functions, that
is anti- and proapoptotic; survival was triggered through the
activation of RSK1, with cell death eventually emerging
through the activation of p53.
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Figure 10. Interaction of P-ERK1/2 and ERK1/2 with p53 and RSK1. A375
and BLM cells were treated with 100mM cisplatin alone and in combination
with 25mM U0126. Immunoprecipitation (IP) with a P-ERK1/2 antibody and
Western blot analysis with P-p53(ser 6) and P-RSK1 were performed.
(a) Cisplatin induced the interaction of P-ERK1/2 with P-p53 (Ser6) as well as
with P-RSK1 in A375 cells. Inhibition of ERK1/2 activation strongly reduced
the cisplatin-induced interaction between P-ERK1/2 and P-p53 (Ser6).
(b) Treatment of BLM with cisplatin had no effect on the interaction between
P-ERK1/2 and P-p53 (Ser6). In contrast, cisplatin again induced the interaction
between P-ERK1/2 and P-RSK1. (c) Cisplatin induced the interaction of
ERK1/2 with RSK1. c, untreated cells.
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Figure 11. Inhibition of ERK1/2 blocks the activation of RSK1. SiRNA against
ERK1/2 (p42 and p44) was found to block the activation of P-RSK1 in A375
cells and showed a strong reduction in BLM cells. SiRNA mediated inhibition
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M, Mock transfected cells; Scr, scrambled siRNA; p42 and p44, the two
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Figure 12. SiRNA mediated decrease of RSK1. A375 and BLM were treated
with 10 nmol siRNA for 72 hours. (a) SiRNA mediated reduction of RSK1
expression in A375 and BLM cells. (b) Cisplatin treatment following
siRNA-mediated reduction of RSK1 showed increased PARP cleavage in
comparison with cisplatin treatment in control siRNA-treated cells.
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DISCUSSION
The MAPK signaling pathway is involved in the regulation of
cell growth and development, with a dysbalance leading to
abnormal proliferation and eventual tumorigenicity. Activation
of ERK appears to be required for many cells to pass the G1
restriction point and to enter the S-phase, during which
cellular DNA replication takes place (Lenormand et al., 1993).
Our data on ERK1/2 expression in melanoma metastasis
samples revealed high ERK activity, which caused disturbed
apoptosis and increased tumor cell proliferation. In mela-
noma, one reason for the high P-ERK1/2 levels may result
from the mutation of the BRAF gene as a constitutive activator
in RAS–Raf signaling (Davies et al., 2002), but another cause
seems to be the high production of growth factors like EGF.
The expression of the EGFR on NHM and its importance for
melanoma development has been discussed controversially
(Shahbazi et al., 2002; Stove et al., 2003; Grahn and Isseroff,
2004). In a recent study, we showed high EGFR expression in
melanoma metastases and NHM (Mirmohammadsadegh
et al., 2005). This permitted us to investigate whether EGF
was responsible for the phosphorylation of ERK1/2 in
melanoma. Indeed, rEGF induced JAK-1 and SRC-mediated
activation of ERK1/2 in NHM and in melanoma cell lines
A375 and BLM, respectively, and was thus likely contributing
to the P-ERK1/2 dysbalance in melanoma. In addition, EGF
was shown to be involved in melanocyte proliferation
through EGFR-mediated activation of STAT3 and STAT5
(Mirmohammadsadegh et al., 2006).
For treatment of malignant melanoma, it is important to
know if a reduction in ERK1/2 phosphorylation will permit
more successful therapy. Treatment with cisplatin, one of the
most potent antitumor agents, did not decrease ERK1/2
phosphorylation in vitro; to the contrary, it increased the
activation of ERK1/2.
The role of cisplatin-activated ERK1/2 with regard to
apoptosis has also been discussed controversially. Depending
on the type of cancer, cisplatin-induced ERK1/2 activation
has shown both pro- or antiapoptotic functions (Persons et al.,
1999; Wang et al., 2000; Wei et al., 2004). This discrepancy,
however, needs further study to define the role of cisplatin-
activated ERK1/2 in apoptosis of melanoma. Inhibition of
ERK1/2 activation by specific MEK inhibitors and co-
treatment with cisplatin induced strong caspase 3- and
PARP-mediated apoptosis in our study as in ovarian cancer
(Persons et al., 1999). To our surprise, cisplatin-activated
ERK1/2 was able to activate the cell survival protein RSK1 as
well as the tumor suppressor protein p53 in a cell type-
specific manner (Woessmann et al., 2002). ERK1/2 has been
shown to phosphorylate the members of the RSK family by
interaction through a docking site located near the C-
terminus (Roux et al., 2003). RSK plays an active role in
nuclear signaling by phosphorylating the cyclic AMP
response element-binding protein (Xing et al., 1996), cFos
(Chen et al., 1993), and IkB (Schouten et al., 1997), leading
to cell survival and proliferation. The role of p53 induced by
cytotoxic drugs and ERK signaling has been partially studied
in ovarian cancer, where accumulation and phosphorylation
of p53 has been demonstrated (Persons et al., 1999).
Phosphorylation of p53 in response to chemotherapy usually
occurs at serine 15 and less frequently at other sites
(Eisenmann et al., 2003).
Our findings are in concert with a previous study, which
supported a role of ERK signaling in activating RSK1 in
melanoma, leading to inactivation of the proapoptotic BAD
and to increased survival of melanoma cells (Eisenmann
et al., 2003). Under normal conditions, we could not detect
RSK1 activation in A375 and BLM cells, which suggests that
ERK1/2-activated RSK1 occurs only under cellular stress such
as exposure to cytotoxic drugs (e.g., cisplatin).
Our study argues that high ERK1/2 phosphorylation in
melanoma supports tumor progression and protects tumor
cells from apoptosis. Furthermore, these observations indi-
cate that ERK1/2 activation partially protects cells from
cisplatin-mediated apoptosis, through the activation of RSK1.
Inhibition of ERK1/2 phosphorylation by specific inhibitors
and RSK1 activation by RNAi technology led to earlier and
stronger apoptosis as detected by the expression of cleaved
caspase 3 and PARP. Therefore, simultaneous treatment with
cisplatin and U0126 may result in synergistic therapeutic
effects at tolerable doses of cisplatin. Further investigation on
the mechanism of how the EGF pathway activates ERK and
studying its inhibition in combination with anticancer drugs
may be helpful in improving melanoma therapy. The
significance of phosphorylated RSK1 deserves further study
as a therapeutic marker in clinical specimens.
MATERIALS AND METHODS
Cell culture
NHMs were cultured in PMA-free melanocyte medium (both
obtained from PromoCell, Heidelberg, Germany). Cell culture was
maintained in a 371C incubator in a moist atmosphere of 5% CO2.
The human melanoma cell lines BLM, MV3, M13, and A375 were
cultured in DMEM (Invitrogen-Gibco, Karlsruhe, Germany) supple-
mented with 10% fetal calf serum, 100 U/ml penicillin, and 100 mg/
ml streptomycin. As a positive control, the HaCaT epithelial cell line
was used. Inhibitors of MEK-1/2 (U0126) and cisplatin were obtained
from Sigma-Aldrich, Taufkirchen, Germany. rEGF was obtained from
BioSource, Solingen, Germany.
Tumor specimens
The melanoma metastasis samples were extracted from several
different patients, who signed informed consent. Samples were snap-
frozen in liquid nitrogen and homogenized using a dismembrator
(Braun-Melsungen, Melsungen, Germany). The powder was imme-
diately transferred into ice-cold lysis buffer containing 25 mM
hydroxyethylpiperazine ethanesulfonic acid pH 7.9, 50 mM NaF,
15 mM Triton X-100, 5 mM EDTA, 100 mM NaCl, and 1 tablet
protease inhibitor cocktail per 10 ml buffer (Roche Applied Science,
Mannheim, Germany) for Western blot analysis. The study was
conducted according to the Declaration of Helsinki Principles and
was approved by the Institutional Review Board.
Western blot analysis
Cells were washed twice with ice-cold phosphate buffered saline
and lysed in lysis buffer (see above). The samples were pretreated
with ultrasound (10 pulses on ice; Sonoplus, Bandelin Electric,
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Germany) and were centrifuged at 14,000 g for 20 minutes at 41C.
The protein concentration of the cellular extracts was determined
using the advanced protein assay reagent (TEBU, Germany). Twenty
micrograms of protein extract were electrophoresed on 4–12%
NuPage Bis–Tris–Glycine gels (Invitrogen, Germany) for 2 hours at
120 V. Proteins were blotted onto polyvinylidene fluoride mem-
branes (Roth, Karlsruhe, Germany) at 160 mA for 60 minutes using a
tank blot system. The membranes were blocked with 1% non-fat dry
milk powder in 10 mM Tris–HCl (pH 7.5), 150 mM NaCl, and 0.05%
Tween 20 (TBST buffer) for 1 hour at 41C and washed three times
with TBST. Immunostaining was performed using antibodies against
ERK1/2, P-ERK1/2, cleaved PARP, PARP, cleaved caspase 3, caspase
3, caspase 8, caspase 9, p53 and P-RSK1, Bcl-2 (each Cell Signaling,
New England Biolabs, Frankfurt, Germany). Bax and RSK1 anti-
bodies were obtained from Becton Dickinson Bioscences, Heidel-
berg, Germany. a-tubulin antibody was purchased from Oncogene
Research Products, Calbiochem, Darmstadt, Germany. Bound anti-
body was visualized using the chemiluminescence detection system
(Pierce, Rockford, IL) following the supplier’s instructions.
Immunoprecipitation
Cells were lysed in Western blot lysis buffer (see above) and
incubated with P-ERK1/2, ERK1/2 (Cell Signaling, New England
Biolabs, Germany) antibodies overnight at 41C with constant
rotation followed by incubation with immobilized protein A/G
(Pierce) for 2 hours. Immunoprecipitates were washed five times
with lysis buffer and then resuspended in Laemmli buffer, boiled,
and analyzed by Western blotting using anti-p53, anti-P-p53-serine
6, anti-RSK1, and anti-P-RSK1 (threonine/serine positions 359/363).
RNA interference
SiRNAs against p42 and p44 (ERK1/2) were provided by Dharmacon
(Solingen, Germany). Cells (2 105) were incubated with 100 nM
siRNA transfection solution without fetal calf serum and antibiotics
for 4 hours. At 24 and 48 hours, cells were detached with trypsin and
centrifuged for 5 minutes at 500 g before protein extraction as
described above. SiRNA against RSK1 was obtainted from Qiagen
(Germany). The transfections were performed in six-well plates
according to the manufacturer’s recommended protocol.
FACS analysis using the Annexin-V/PI method
The appearance of phosphatidyleserine on the extracellular side of
membrane was evaluated with annexin-V/PI method. The melanoma
cell lines A375 and BLM were exposed to U0126 and cisplatin,
trypsinized, and washed twice in ice-cold phosphate-buffered saline
before resuspension in 1 binding buffer (Invitrogen). Thereafter,
5ml of Annexin V-FITC (Vybrant; Invitrogen) and 5 ml propidium
iodide (100 mg/ml) were added to 100 ml of cell suspension and
incubated for 15 minutes at room temperature protected from light.
Finally, 400 ml of binding buffer were added to the samples and
handled ice-cold until analysis. The fluorescent signals of FITC and
PI was detected by FL1 at 518 nm and FL2 at 620 nm, respectively,
on a FACSCalibur (Becton Dickinson Bioscences) and apoptotic cells
(annexin-V-positive/PI-negative) were quantified.
MTT and BrdU assay
Melanoma cells were exposed to U0126 and cisplatin in a 96-well
plate for 24, 48, and 72 hours cells before incubation with 10 ml of
5 mg/ml stock of MTT (Sigma) for 2 hours at 371C. Upon solubiliza-
tion, the number of surviving cells was measured at A540 nm. BrdU
assays were performed according to the supplier’s instructions
(Roche Applied Science).
Statistical analysis
All data were analyzed by coefficient of variation. A coefficient of
variation value greater than 0.2 was considered statistically
significant.
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SUPPLEMENTARY MATERIAL
Figure S1. U0126-mediated reduction of P-ERK1/2.
Figure S2. Detection of RSK1 and P-RSK1 in melanoma metastases by
Western blotting.
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